Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ43OM)

• Drug Name: PMID26560530-Compound-25 Drug Info
• Cross-matching ID:
  PubChem CID: 2194
  ChEBI ID: CHEMBL31221
  CAS Number: CAS 532-11-6
  TTD Drug ID: DMZ43OM

Molecule-Related Drug Atlas

Drug(s) Targeting Tissue transglutaminase (TG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ZED1227	DMDXEN5	Coeliac disease	DA95	Phase 2	[3]
PMID26560530-Compound-13	DMKF26Z	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-54	DM2X4R0	N. A.	N. A.	Patented	[1]
Triazole derivative 1	DM9QB2S	N. A.	N. A.	Patented	[1]
Acyl piperidine derivative 3	DMIDUB4	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-14	DM52MIK	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-1	DMSI7F2	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-3	DM92OT0	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-11	DMZ5UST	N. A.	N. A.	Patented	[1]
Chloroacetyl ester derivative 1	DMW4J0P	N. A.	N. A.	Patented	[1]

Drug(s) Affected By Calcitonin (CALCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[4]
Fructose	DM43AN2	Vomiting	MD90	Approved	[5]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[6]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[7]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[8]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[9]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[4]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[10]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[11]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[12]

Drug(s) Affected By Protachykinin-1 (TAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[13]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[14]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[15]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[17]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[4]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[18]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tissue transglutaminase (TG2)	TT2F4OL	TGM2_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Calcitonin (CALCA)	OTZ11LHB	CALC_HUMAN	Gene/Protein Processing	[2]
Protachykinin-1 (TAC1)	OTM842YW	TKN1_HUMAN	Gene/Protein Processing	[2]

References

• [1] Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
• [2] Enhancement of salivary secretion and neuropeptide (substance P, alpha-calcitonin gene-related peptide) levels in saliva by chronic anethole trithione treatment. J Pharm Pharmacol. 2001 Dec;53(12):1697-702. doi: 10.1211/0022357011778098.
• [3] Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022 May 17;11(10):1667.
• [4] Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 2002 Nov;54(11):1559-63. doi: 10.1211/002235702117.
• [5] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [6] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [7] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [8] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [9] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [10] Transient receptor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived calcitonin gene-related peptide. Regul Pept. 2008 Oct 9;150(1-3):66-72. doi: 10.1016/j.regpep.2008.05.007. Epub 2008 Jun 3.
• [11] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [12] Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
• [13] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [14] Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology (Oxford). 2006 Jun;45(6):765-70. doi: 10.1093/rheumatology/kei253. Epub 2006 Jan 31.
• [15] Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci. 2005 Mar;21(6):1712-8. doi: 10.1111/j.1460-9568.2005.04002.x.
• [16] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [17] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [18] Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
• [19] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.